Overview

Predicting the Response to Montelukast by Genetic Variation in Asthmatics

Status:
Completed
Trial end date:
2006-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to examine a specific variation in the genetic code for an enzyme (LTC4 synthase) which plays an important role in the airway inflammation associated with asthma. We hypothesize that asthmatic patients with this variant gene will have a better response to montelukast than patients with the wild type gene, as measured by the ability of montelukast to protect against a hypertonic saline challenge.
Phase:
Phase 3
Details
Lead Sponsor:
Brigham and Women's Hospital
Collaborator:
Merck Sharp & Dohme Corp.
Treatments:
Montelukast